Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide + dolutegravir PK in HIV-1 patients with end-stage renal disease on hemodialysis
ChiCTR2100045021Phase 4Recruiting
- Sponsor
- Chongqing Public Health Medical Treatment Center
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albuvirtide and dolutegravir in human immunodeficiency virus infection (HIV) and end-stage kidney disease (ESKD), sponsored by Chongqing Public Health Medical Treatment Center. Primary endpoint: Extraction rate of albuvirtide during hemodialysis. Started Apr 2021; status: recruiting.
02
Drugs
albuvirtidedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2100045021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045021.